BioTime Subsidiary, Asterias Biotherapeutics, and Cancer Research UK and Cancer Research Technology Partner for Clinical Trial of Immunotherapy Vaccine for Lung Cancer

September 11, 2014 BioTime, Inc. announced that its subsidiary Asterias Biotherapeutics, Inc. has reached an agreement with Cancer Research UK and Cancer Research Technology (CRT), the charity’s development and commercialization arm, to conduct a clinical trial of Asterias’ novel immunotherapy treatment AST-VAC2 in subjects with non-small cell lung cancer. AST-VAC2 is a non-patient specific (allogeneic) cancer vaccine designed to stimulate patients’ immune …

BioTime Receives FDA Premarket Notification Clearance for Premvia™ 510(k)

August 12th, 2014 -BioTime, Inc. (NYSE MKT: BTX) today announced that it has received notice from the FDA’s Center for Devices and Radiologic Health that Premvia™ has been cleared for marketing as a Class II medical device. Premvia™ is the first FDA-cleared member of BioTime’sHyStem® family of hydrogels, which are designed to mimic the natural structures of the human body’s extracellular matrix. According to …

BioTime Subsidiary Asterias Biotherapeutics Raises $13.0 Million in Equity Financing

Capital infusion provides funding to advance Asterias’ therapeutic programs Substantially strengthens Asterias’ cash position June 17, 2014 BioTime, Inc. announced today that its subsidiary Asterias Biotherapeutics, Inc. (“Asterias”), has raised $12.5 million through the sale of 5,000,000 BioTime common shares held by Asterias and the issuance of warrants to purchase 5,000,000 shares of Asterias Series B Common Stock. The majority of …